mp.weixin.qq.com·· 10 hours agoScore90
Chia Tai Tianeeng TQB2102 Cuts Risk of Progression or Death by 71% in HER2-Low Advanced Breast Cancer in APEX-Breast01 Phase 3
In brief
At ESMO 2026, Chia Tai Tianeeng presented randomized phase 3 data for TQB2102, a HER2 dual-epitope ADC, from the APEX-Breast01 trial. In HER2-low advanced breast cancer, TQB2102 reduced the risk of disease progression or death by 71% compared with chemotherapy.
Source: mp.weixin.qq.com · mp.weixin.qq.com